EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials

Mable Pereira, Ancy Jenil Franco, Karthik Chintharala, Ana Carolina Putini Vieira, Ana Carolina Ventura de Santana de Jesus, Paweł Łajczak, Khaled Alhwaishel, Mario Saul Lira Castañeda, Elizabet Taylor Pimenta Weba, Kristian Reich

Inflammopharmacology · 2025

DOI: 10.1007/s10787-025-01658-5 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Mable Pereira und 9 weiteren Autor:innen. Beteiligte Einrichtung: Lincoln American University School of Medicine, 8A & 8B, Water & Barrack Street, Kingston, 413741, Guyana. mablepereira27@gmail.com. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Mirikizumab, an interleukin-23 (IL-23) p19 subunit inhibitor, has emerged as a promising treatment for moderate-to-severe plaque psoriasis. Despite its promising results, a comprehensive synthesis of clinical data is essential to assess its overall efficacy and safety profile. METHODS: We searched PubMed, Embase, and Cochrane for studies assessing mirikizumab in moderate-to-severe psoriasis. A random-effects model using Inverse Variance (IV) computed mean differences (MD) for continuous outcomes and risk ratios (RR) for binary endpoints. Risk Difference (RD) studies were analysed using generic inverse variance (GIV) in Review Manager. Statistical analyses were conducted using R software version 4.2.1, following PRISMA guidelines. RESULTS: This analysis of three RCTs involving 1,649 adult patients over 16-52 weeks demonstrated mirikizumab's significant efficacy in treating psoriasis. At 16 weeks, mirikizumab substantially reduced Body Surface Area (BSA) to < 1% (RR: 34.53, p < 0.001) and improved PASI scores (PASI 100 RR: 25.94, PASI 90 RR: 11.50, PASI 75 RR: 10.47, all p < 0.001). Static Physician's Global Assessment (sPGA) scores of 0/1 were achieved (RR: 12.48, p < 0.001). Quality of life measures also improved significantly, with increases in SF-36 Physical and Mental Component Summaries (MD: 4.02 and 3.53 respectively, p < 0.01) and Dermatology Life Quality Index (DLQI) scores of 0/1 (RD: 0.51, p < 0.00001). Importantly, the safety profile of mirikizumab was comparable to the control, with no significant differences in the overall incidence of adverse effects (RR: 0.97; 95% CI: 0.86-1.10) or in serious adverse effects (RR: 1.61; 95% CI: 0.55-4.73). These results collectively demonstrate the efficacy and safety of mirikizumab in treating psoriasis, with significant improvements across multiple clinical and quality-of-life measures. CONCLUSION: This meta-analysis demonstrates that mirikizumab significantly reduces psoriasis severity and improves quality of life, with a favourable safety profile. These findings support its use as a valuable treatment option for moderate-to-severe plaque psoriasis. Further research is needed to assess long-term outcomes and comparative effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedHumansRandomized Controlled Trials as TopicTreatment OutcomeSeverity of Illness IndexQuality of LifeInterleukin-23 Subunit p19

Stichwörter der Autor:innen

Interleukin-23 inhibitorMirikizumabPsoriasis

Substanzen

Interleukin-23 Subunit p19Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Lincoln American University School of Medicine, 8A & 8B, Water & Barrack Street, Kingston, 413741, Guyana. mablepereira27@gmail.com.
  • Sri Muthukumaran Medical College Hospital and Research Institute, Kundrathur Main Rd, Near Mangadu, Chikkarayapuram, Sikkarayapuram , Chennai, Tamil Nadu, India.
  • NRI Academy of Medical Sciences, Chinakakani, Guntur , Managalgiri, Andhra Pradesh, 522 503, India.
  • University of Santo Amaro, 340, Rua Prof Enéas de Siqueira Neto, São Paulo, São Paulo, Brazil.
  • Escola Bahiana de Medicina e Saúde Pública, Bahiana School of Medicine and Public Health, Avenida Dom João VI, 275, Brotas, Salvador, Bahia, 40290-000, Brazil.
  • Medical University of Silesia, Jordana 19, 41-808, Zabrze, Poland.

Zitieren

APA

Pereira, M., Franco, A. J., Chintharala, K., Vieira, A. C. P., de Santana de Jesus, A. C. V., Łajczak, P., Alhwaishel, K., Castañeda, M. S. L., Weba, E. T. P., & Reich, K. (2025). Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01658-5

Vancouver

Pereira M, Franco AJ, Chintharala K, Vieira ACP, de Santana de Jesus ACV, Łajczak P, et al. Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01658-5

BibTeX
@article{Pereira2025,
  author = {Pereira, Mable and Franco, Ancy Jenil and Chintharala, Karthik and Vieira, Ana Carolina Putini and de Santana de Jesus, Ana Carolina Ventura and Łajczak, Paweł and Alhwaishel, Khaled and Castañeda, Mario Saul Lira and Weba, Elizabet Taylor Pimenta and Reich, Kristian},
  title = {Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-025-01658-5}
}
Kostenlos starten →